Semaglutide vs. Tirzepatide: Differences, Results and Costs

Tirzepatide produced greater average weight loss than semaglutide at the studied doses in SURMOUNT-5. Individual choice still depends on risks, tolerability, access and goals; the trial does not establish compounded-product equivalence.

This guide explains what the science actually shows, what licensed providers consider when choosing between them, and how to think about your own situation.

---

SURMOUNT-5 compared tirzepatide and semaglutide at specific doses in adults with obesity without type 2 diabetes. Its results do not establish compounded-product equivalence or predict your response. Source: SURMOUNT-5 direct comparison

How Each Medication Works

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after eating — signaling your brain that you’re full, slowing stomach emptying, and reducing appetite. It also improves insulin sensitivity.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It works on two hormonal pathways simultaneously: GLP-1 (the same as semaglutide) and GIP (glucose-dependent insulinotropic polypeptide). This dual action appears to amplify the metabolic effects beyond what GLP-1 alone achieves.

In simple terms: tirzepatide hits two targets instead of one, which is why clinical trials have shown it produces somewhat greater average weight loss.

---

What the Research Shows

The SURMOUNT-1 trial of tirzepatide showed average weight loss of 20.9% of body weight at the highest dose (15mg) over 72 weeks in people without diabetes.

The STEP 1 trial of semaglutide showed average weight loss of 14.9% of body weight at the 2.4mg dose over 68 weeks in people without diabetes.

Both are dramatic improvements over older weight-loss medications. Both significantly outperform diet and exercise alone.

Important caveat: These are averages from clinical trials. Individual results vary significantly based on genetics, adherence, lifestyle, and other factors. Some patients lose more on semaglutide than the tirzepatide average — and vice versa.

---

Side Effect Profile

Both medications share similar side effects, primarily because of the overlapping GLP-1 mechanism:

• Nausea — most common, especially when starting or increasing dose
• Vomiting — typically mild and improves over time
• Diarrhea or constipation — varies by patient
• Fatigue — common in the first weeks
• Reduced appetite — the desired effect, but can lead to insufficient nutrition if not managed

Does tirzepatide cause more side effects?

Clinical data suggests the side effect profiles are similar, though some patients report that the GIP component in tirzepatide causes slightly more nausea at equivalent doses. However, since tirzepatide also tends to produce stronger appetite suppression, many patients find the trade-off worthwhile.

The key to minimizing side effects for either medication is a slow, gradual dose escalation — which is standard practice at REMEVi.

---

Cost Comparison

Brand prices vary by formulation, dose, coverage and offer eligibility. Confirm the supply length and ongoing price in current manufacturer terms before comparing with a compounded preparation. Source: Ozempic manufacturer savings terms Source: Zepbound manufacturer savings terms

Compounded versions made by state-licensed compounding pharmacies are non-FDA-approved preparations containing the peptides semaglutide or tirzepatide, at a fraction of the cost; they are not generic versions of the branded drugs.

At REMEVi:

• Compounded semaglutide is one flat price — the same at every dose — published on our semaglutide page (all-inclusive)
• Compounded tirzepatide is one flat price — the same at every dose — published on our tirzepatide page (all-inclusive)

Both include clinical evaluation, medication, shipping, and bilingual care coordinator access — no hidden fees.

---

Who Should Consider Semaglutide?

Semaglutide tends to be the right starting point if:

• You are new to GLP-1 therapy and want to start with a well-established option
• Cost is a significant consideration
• You have a history of sensitivity to new medications and prefer a more conservative approach
• Your weight-loss goal is 10–20% of body weight

---

Who Should Consider Tirzepatide?

Tirzepatide may be the better fit if:

• You have already tried semaglutide and reached a plateau
• You have a higher BMI and are targeting more significant weight loss
• You have type 2 diabetes or insulin resistance (tirzepatide has stronger glycemic effects)
• You want to maximize average weight-loss outcomes from the start

---

The Decision Is Personal

The right medication depends on your full medical picture — not just the comparison chart. At REMEVi, every patient is evaluated by a licensed US provider who reviews your health history, current medications, BMI, metabolic markers, and goals before recommending a protocol.

If you’re unsure which to choose, you don’t have to figure it out alone. Your REMEVi care coordinator (available in English and Spanish) can walk you through the options before you even complete the intake form.

---

Ready to Get Started?

REMEVi offers compounded semaglutide at one flat price — the same at every dose — published on our semaglutide page and compounded tirzepatide at one flat price — the same at every dose — published on our tirzepatide page — both all-inclusive with clinical review, shipping included, and bilingual support.

The intake form takes 2 minutes. Clinical review happens within 24 hours. Medication arrives within 3–4 days.

Start your free consultation →

---

This article is for informational purposes only and does not constitute medical advice. Consult with a licensed provider — including through REMEVi’s telehealth platform — before starting any prescription medication.